Entyvio Side Effects, Infusion Time, and Treatment Guide

Entyvio (vedolizumab) is a gut-selective biologic infusion used to treat moderate to severe Crohn’s disease and ulcerative colitis. Unlike systemic immunosuppressants, it targets inflammation specifically in the gastrointestinal tract. Infusions take approximately 30 minutes after a loading phase, and most patients tolerate it well.

What Makes Entyvio Different: Gut-Selective Action

Most biologic medications for inflammatory bowel disease (IBD) work by dampening the entire immune system. TNF inhibitors like Remicade, for example, block an inflammatory protein throughout the body. That broad approach is effective, but it also raises the risk of infections in parts of the body that have nothing to do with the gut.

Entyvio takes a fundamentally different approach. It is designed to act primarily in the gastrointestinal tract, leaving the rest of the immune system largely intact. For patients who are concerned about the systemic immunosuppression that comes with other biologics, or who have experienced infections on prior therapies, this gut-selective mechanism can be a meaningful advantage.

How Entyvio Works

Entyvio (vedolizumab) is a monoclonal antibody that blocks a protein called alpha-4-beta-7 integrin. This protein sits on the surface of certain white blood cells and acts like an address label, directing those cells to travel into gut tissue. In IBD, too many inflammatory white blood cells migrate into the intestinal wall, causing the chronic damage that leads to symptoms like diarrhea, bleeding, pain, and urgency.

By blocking alpha-4-beta-7 integrin, vedolizumab prevents these inflammatory cells from reaching the gut lining. Over time, this reduces intestinal inflammation and allows the tissue to heal. Because this integrin is specific to gut-homing immune cells, the drug does not broadly suppress immune function elsewhere in the body.

Dosing and Infusion Schedule

Entyvio uses a fixed dose of 300 mg, regardless of body weight. This differs from weight-based biologics like Remicade. The treatment schedule includes a loading phase followed by maintenance:

One important note about Entyvio: it often works more gradually than TNF inhibitors. While some patients feel improvement within the first few weeks, clinical studies show that full response may take 14 weeks or longer, particularly for Crohn’s disease. Patients should discuss realistic timelines with their gastroenterologist so they do not abandon an effective treatment prematurely.

What the Infusion Is Like

The Entyvio infusion time is approximately 30 minutes, making it one of the shorter biologic infusions. After the infusion, patients are typically monitored for about 30 minutes to watch for any immediate reactions. Total appointment time is usually around one to one-and-a-half hours, including check-in, vitals, and observation.

Compared to the two-plus hours required for infliximab infusions, this shorter duration is a practical advantage for patients balancing treatment with work, school, or caregiving. Learn more about the general infusion therapy process for context on what to expect.

Entyvio Side Effects

Entyvio is generally well tolerated. In clinical trials, the most commonly reported side effects included:

• Nasopharyngitis (common cold symptoms)
• Headache
• Joint pain (arthralgia)
• Nausea
• Upper respiratory tract infections
• Fatigue
• Cough
• Back pain

Infusion reactions occurred in approximately 4% of patients in clinical trials. These were generally mild and included symptoms like itching, rash, or nausea during or shortly after infusion. Severe infusion reactions, including anaphylaxis, have been reported but are rare.

According to the Crohn’s & Colitis Foundation, vedolizumab’s safety profile compares favorably to other biologic options, particularly regarding infection risk. This is supported by data from the GEMINI long-term safety studies, which tracked patients for several years on continuous therapy.

Serious Risks to Know About

Additional serious risks include:

• Liver injury — Cases of elevated liver enzymes and hepatitis have been reported. Liver function monitoring may be performed.
• Allergic reactions — Anaphylaxis is possible, though rare. Emergency medications should be available during infusions.
• Infections — While the overall infection rate is lower than with systemic immunosuppressants, patients should still report fevers, persistent symptoms, or signs of infection promptly.

The FDA notes that patients should not receive live vaccines while on Entyvio. Non-live vaccines can be administered, and patients should ideally be up to date on vaccinations before starting treatment.

Entyvio vs. Remicade for IBD

Choosing between Entyvio and Remicade depends on several factors: disease severity, prior treatment history, patient preference, and individual risk factors. For a detailed breakdown, see the Entyvio vs. Remicade comparison. Here is a general overview:

Some gastroenterologists consider Entyvio a first-line biologic for ulcerative colitis due to strong efficacy data and favorable safety. For Crohn’s disease, it may be preferred when infection risk is a primary concern, though TNF inhibitors may be chosen for patients with fistulizing disease or those needing rapid symptom relief.

Entyvio Home Infusion

The short infusion time makes Entyvio a natural fit for home infusion. Many patients transition to home-based treatments after completing their loading doses in a clinical setting without reactions. Entyvio home infusion involves a registered nurse visiting the patient’s home to administer the 30-minute infusion and stay for the observation period afterward.

For patients receiving infusions every eight weeks, eliminating travel time and waiting rooms adds up to significant convenience over the course of a year. Those curious about how insurance handles home infusion can explore coverage details to understand their options.